Evidence map›Paper›PMID 27840658›Full record

ArticleClinical & experimental neuroimmunology2014

Evaluation of aquaporin-4 antibody assays.

Patrick J Waters, Sean J Pittock, Jeffrey L Bennett, Sven Jarius, Brian G Weinshenker, Dean M Wingerchuk

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental neuroimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Patrick J WatersNeuroimmunology Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
Sean J PittockDepartments of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Jeffrey L BennettDepartments of Neurology and Ophthalmology, University of Colorado Denver, Aurora, CO, USA.
Sven JariusMolecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Brian G WeinshenkerDepartments of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Dean M WingerchukDepartment of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
Heidelberg University · DEJohn Radcliffe Hospital · GBMayo Clinic · USMayo Clinic in Arizona · USUniversity of Colorado Denver · US

Funding

Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis OpticaR01EY022936 · NEI · UNIVERSITY OF COLORADO DENVER · PI BENNETT, JEFFREY L · 2013 to 2022
$3.8M
CNS Demyelinating Autoimmunity Targeting Water Channel ComplexesR01NS065829 · NINDS · MAYO CLINIC ROCHESTER · PI PITTOCK, SEAN JOSEPH · 2010 to 2014
$1.7M
NEI NIH HHS R01 EY022936NINDS NIH HHS R01 NS065829
6 · The paper itself

Abstract

Aquaporin-4 (AQP4) is a water channel protein that is most highly, but not exclusively, expressed in the central nervous system. In 2005 AQP4 was shown to be the antigenic target of neuromyelitis optica-immunoglobulin G (NMO-IgG, or AQP4-IgG), an antibody found specifically in patients with NMO and in formes frustes of NMO, such as longitudinally extensive transverse myelitis (LETM) or optic neuritis (ON). This discovery facilitated the clinical, pathological, and radiological distinction of NMO and the spectrum of NMO-related disorders from classical multiple sclerosis. In addition to its use as a diagnostic tool, AQP4-IgG predicts a high risk of relapse in patients with a clinically isolated syndrome of either LETM or ON. As disability in NMO is attack-related, early diagnosis and treatment are predicted to have a major effect on long-term disability. Thus, the importance of sensitive and specific assays to detect AQP4-IgG cannot be overstated. Both academic institutions and commercial companies have developed assays to identify AQP4-IgG in patients' sera or cerebrospinal fluid. Both AQP4 isoforms from different species have been used as the antigenic target in the form of frozen tissue sections in indirect immunofluorescence assays, partially purified protein for fluorescence immunoprecipitation assay, radioimmunoprecipita-tion assay or enzyme-linked immunosorbent assay, or transfected into cells for cell based assays or flow cytometry. We carried out a systematic review of the literature reporting different methodologies used to identify AQP4-IgG, examine whether longitudinal AQP4-IgG titers predict relapses in seropositive patients, and attempt to establish a reasonable timeframe for retesting negative serum samples.

Indexed as

antibodyaquaporin-4-immunoglobulin Gmultiple sclerosisneuromyelitis opticaneuromyelitis optica-immunoglobulin G

Identifiers

PMID27840658
PMCPMC5102503
OpenAlexW1979550850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.